The global market for Peptide and Oligonucleotide CDMO was valued at US$ 1918 million in the year 2024 and is projected to reach a revised size of US$ 3704 million by 2031, growing at a CAGR of 10.0% during the forecast period.

Peptide and Oligonucleotide CDMO Market

North American market for Peptide and Oligonucleotide CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Peptide and Oligonucleotide CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Peptide and Oligonucleotide CDMO in Pharmaceutical and Biotechnology Companies is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Peptide and Oligonucleotide CDMO include Lonza Group Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Catalent, Inc., Genscript Biotech Corporation, Polypeptide Group, Bachem Holding AG, Wuxi Apptec Co., Ltd., Ajinomoto Co., Inc., Rentschler Biopharma SE, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Peptide and Oligonucleotide CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide and Oligonucleotide CDMO.

The Peptide and Oligonucleotide CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peptide and Oligonucleotide CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Peptide and Oligonucleotide CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Peptide and Oligonucleotide CDMO Market Report

Report Metric	Details
Report Name	Peptide and Oligonucleotide CDMO Market
Accounted market size in year	US$ 1918 million
Forecasted market size in 2031	US$ 3704 million
CAGR	10.0%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Peptide CDMO Oligonucleotide CDMO
Segment by Application	Pharmaceutical and Biotechnology Companies Research Institutes Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Lonza Group Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Catalent, Inc., Genscript Biotech Corporation, Polypeptide Group, Bachem Holding AG, Wuxi Apptec Co., Ltd., Ajinomoto Co., Inc., Rentschler Biopharma SE, Corden Pharma GmbH, Senn Chemicals AG, Almac Group, Lonza Custom Manufacturing, Creative Peptides, Swiss Customized Synthesis, Syngene, Eurogentec
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide and Oligonucleotide CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Peptide and Oligonucleotide CDMO Market growing?

Ans: The Peptide and Oligonucleotide CDMO Market witnessing a CAGR of 10.0% during the forecast period 2025-2031.

What is the Peptide and Oligonucleotide CDMO Market size in 2031?

Ans: The Peptide and Oligonucleotide CDMO Market size in 2031 will be US$ 3704 million.

Who are the main players in the Peptide and Oligonucleotide CDMO Market report?

Ans: The main players in the Peptide and Oligonucleotide CDMO Market are Lonza Group Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Catalent, Inc., Genscript Biotech Corporation, Polypeptide Group, Bachem Holding AG, Wuxi Apptec Co., Ltd., Ajinomoto Co., Inc., Rentschler Biopharma SE, Corden Pharma GmbH, Senn Chemicals AG, Almac Group, Lonza Custom Manufacturing, Creative Peptides, Swiss Customized Synthesis, Syngene, Eurogentec

What are the Application segmentation covered in the Peptide and Oligonucleotide CDMO Market report?

Ans: The Applications covered in the Peptide and Oligonucleotide CDMO Market report are Pharmaceutical and Biotechnology Companies, Research Institutes, Others

What are the Type segmentation covered in the Peptide and Oligonucleotide CDMO Market report?

Ans: The Types covered in the Peptide and Oligonucleotide CDMO Market report are Peptide CDMO, Oligonucleotide CDMO

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Peptide and Oligonucleotide CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Peptide CDMO

1.2.3 Oligonucleotide CDMO

1.3 Market by Application

1.3.1 Global Peptide and Oligonucleotide CDMO Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Pharmaceutical and Biotechnology Companies

1.3.3 Research Institutes

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Peptide and Oligonucleotide CDMO Market Perspective (2020-2031)

2.2 Global Peptide and Oligonucleotide CDMO Growth Trends by Region

2.2.1 Global Peptide and Oligonucleotide CDMO Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Peptide and Oligonucleotide CDMO Historic Market Size by Region (2020-2025)

2.2.3 Peptide and Oligonucleotide CDMO Forecasted Market Size by Region (2026-2031)

2.3 Peptide and Oligonucleotide CDMO Market Dynamics

2.3.1 Peptide and Oligonucleotide CDMO Industry Trends

2.3.2 Peptide and Oligonucleotide CDMO Market Drivers

2.3.3 Peptide and Oligonucleotide CDMO Market Challenges

2.3.4 Peptide and Oligonucleotide CDMO Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Peptide and Oligonucleotide CDMO Players by Revenue

3.1.1 Global Top Peptide and Oligonucleotide CDMO Players by Revenue (2020-2025)

3.1.2 Global Peptide and Oligonucleotide CDMO Revenue Market Share by Players (2020-2025)

3.2 Global Peptide and Oligonucleotide CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Peptide and Oligonucleotide CDMO Revenue

3.4 Global Peptide and Oligonucleotide CDMO Market Concentration Ratio

3.4.1 Global Peptide and Oligonucleotide CDMO Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Peptide and Oligonucleotide CDMO Revenue in 2024

3.5 Global Key Players of Peptide and Oligonucleotide CDMO Head office and Area Served

3.6 Global Key Players of Peptide and Oligonucleotide CDMO, Product and Application

3.7 Global Key Players of Peptide and Oligonucleotide CDMO, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Peptide and Oligonucleotide CDMO Breakdown Data by Type

4.1 Global Peptide and Oligonucleotide CDMO Historic Market Size by Type (2020-2025)

4.2 Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Type (2026-2031)

5 Peptide and Oligonucleotide CDMO Breakdown Data by Application

5.1 Global Peptide and Oligonucleotide CDMO Historic Market Size by Application (2020-2025)

5.2 Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Peptide and Oligonucleotide CDMO Market Size (2020-2031)

6.2 North America Peptide and Oligonucleotide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Peptide and Oligonucleotide CDMO Market Size by Country (2020-2025)

6.4 North America Peptide and Oligonucleotide CDMO Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Peptide and Oligonucleotide CDMO Market Size (2020-2031)

7.2 Europe Peptide and Oligonucleotide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Peptide and Oligonucleotide CDMO Market Size by Country (2020-2025)

7.4 Europe Peptide and Oligonucleotide CDMO Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Peptide and Oligonucleotide CDMO Market Size (2020-2031)

8.2 Asia-Pacific Peptide and Oligonucleotide CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region (2020-2025)

8.4 Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Peptide and Oligonucleotide CDMO Market Size (2020-2031)

9.2 Latin America Peptide and Oligonucleotide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2020-2025)

9.4 Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size (2020-2031)

10.2 Middle East & Africa Peptide and Oligonucleotide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country (2020-2025)

10.4 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Lonza Group Ltd.

11.1.1 Lonza Group Ltd. Company Details

11.1.2 Lonza Group Ltd. Business Overview

11.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Introduction

11.1.4 Lonza Group Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.1.5 Lonza Group Ltd. Recent Development

11.2 Thermo Fisher Scientific Inc.

11.2.1 Thermo Fisher Scientific Inc. Company Details

11.2.2 Thermo Fisher Scientific Inc. Business Overview

11.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Introduction

11.2.4 Thermo Fisher Scientific Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.2.5 Thermo Fisher Scientific Inc. Recent Development

11.3 Merck KGaA

11.3.1 Merck KGaA Company Details

11.3.2 Merck KGaA Business Overview

11.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Introduction

11.3.4 Merck KGaA Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.3.5 Merck KGaA Recent Development

11.4 Catalent, Inc.

11.4.1 Catalent, Inc. Company Details

11.4.2 Catalent, Inc. Business Overview

11.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Introduction

11.4.4 Catalent, Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.4.5 Catalent, Inc. Recent Development

11.5 Genscript Biotech Corporation

11.5.1 Genscript Biotech Corporation Company Details

11.5.2 Genscript Biotech Corporation Business Overview

11.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Introduction

11.5.4 Genscript Biotech Corporation Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.5.5 Genscript Biotech Corporation Recent Development

11.6 Polypeptide Group

11.6.1 Polypeptide Group Company Details

11.6.2 Polypeptide Group Business Overview

11.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Introduction

11.6.4 Polypeptide Group Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.6.5 Polypeptide Group Recent Development

11.7 Bachem Holding AG

11.7.1 Bachem Holding AG Company Details

11.7.2 Bachem Holding AG Business Overview

11.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Introduction

11.7.4 Bachem Holding AG Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.7.5 Bachem Holding AG Recent Development

11.8 Wuxi Apptec Co., Ltd.

11.8.1 Wuxi Apptec Co., Ltd. Company Details

11.8.2 Wuxi Apptec Co., Ltd. Business Overview

11.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Introduction

11.8.4 Wuxi Apptec Co., Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.8.5 Wuxi Apptec Co., Ltd. Recent Development

11.9 Ajinomoto Co., Inc.

11.9.1 Ajinomoto Co., Inc. Company Details

11.9.2 Ajinomoto Co., Inc. Business Overview

11.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Introduction

11.9.4 Ajinomoto Co., Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.9.5 Ajinomoto Co., Inc. Recent Development

11.10 Rentschler Biopharma SE

11.10.1 Rentschler Biopharma SE Company Details

11.10.2 Rentschler Biopharma SE Business Overview

11.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Introduction

11.10.4 Rentschler Biopharma SE Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.10.5 Rentschler Biopharma SE Recent Development

11.11 Corden Pharma GmbH

11.11.1 Corden Pharma GmbH Company Details

11.11.2 Corden Pharma GmbH Business Overview

11.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Introduction

11.11.4 Corden Pharma GmbH Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.11.5 Corden Pharma GmbH Recent Development

11.12 Senn Chemicals AG

11.12.1 Senn Chemicals AG Company Details

11.12.2 Senn Chemicals AG Business Overview

11.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Introduction

11.12.4 Senn Chemicals AG Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.12.5 Senn Chemicals AG Recent Development

11.13 Almac Group

11.13.1 Almac Group Company Details

11.13.2 Almac Group Business Overview

11.13.3 Almac Group Peptide and Oligonucleotide CDMO Introduction

11.13.4 Almac Group Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.13.5 Almac Group Recent Development

11.14 Lonza Custom Manufacturing

11.14.1 Lonza Custom Manufacturing Company Details

11.14.2 Lonza Custom Manufacturing Business Overview

11.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Introduction

11.14.4 Lonza Custom Manufacturing Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.14.5 Lonza Custom Manufacturing Recent Development

11.15 Creative Peptides

11.15.1 Creative Peptides Company Details

11.15.2 Creative Peptides Business Overview

11.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Introduction

11.15.4 Creative Peptides Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.15.5 Creative Peptides Recent Development

11.16 Swiss Customized Synthesis

11.16.1 Swiss Customized Synthesis Company Details

11.16.2 Swiss Customized Synthesis Business Overview

11.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Introduction

11.16.4 Swiss Customized Synthesis Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.16.5 Swiss Customized Synthesis Recent Development

11.17 Syngene

11.17.1 Syngene Company Details

11.17.2 Syngene Business Overview

11.17.3 Syngene Peptide and Oligonucleotide CDMO Introduction

11.17.4 Syngene Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.17.5 Syngene Recent Development

11.18 Eurogentec

11.18.1 Eurogentec Company Details

11.18.2 Eurogentec Business Overview

11.18.3 Eurogentec Peptide and Oligonucleotide CDMO Introduction

11.18.4 Eurogentec Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)

11.18.5 Eurogentec Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Merck KGaA

Catalent

Genscript Biotech Corporation

PolyPeptide Group

Bachem Holding AG

Rentschler Biopharma SE

Lonza Custom Manufacturing

Swiss Customized Synthesis

List of Tables

Table 1. Global Peptide and Oligonucleotide CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Peptide CDMO

Table 3. Key Players of Oligonucleotide CDMO

Table 4. Global Peptide and Oligonucleotide CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Peptide and Oligonucleotide CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Peptide and Oligonucleotide CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Peptide and Oligonucleotide CDMO Market Share by Region (2020-2025)

Table 8. Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Peptide and Oligonucleotide CDMO Market Share by Region (2026-2031)

Table 10. Peptide and Oligonucleotide CDMO Market Trends

Table 11. Peptide and Oligonucleotide CDMO Market Drivers

Table 12. Peptide and Oligonucleotide CDMO Market Challenges

Table 13. Peptide and Oligonucleotide CDMO Market Restraints

Table 14. Global Peptide and Oligonucleotide CDMO Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Peptide and Oligonucleotide CDMO Market Share by Players (2020-2025)

Table 16. Global Top Peptide and Oligonucleotide CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide and Oligonucleotide CDMO as of 2024)

Table 17. Ranking of Global Top Peptide and Oligonucleotide CDMO Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Peptide and Oligonucleotide CDMO Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Peptide and Oligonucleotide CDMO, Headquarters and Area Served

Table 20. Global Key Players of Peptide and Oligonucleotide CDMO, Product and Application

Table 21. Global Key Players of Peptide and Oligonucleotide CDMO, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Peptide and Oligonucleotide CDMO Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Type (2020-2025)

Table 25. Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Type (2026-2031)

Table 27. Global Peptide and Oligonucleotide CDMO Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Application (2020-2025)

Table 29. Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Application (2026-2031)

Table 31. North America Peptide and Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Peptide and Oligonucleotide CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Peptide and Oligonucleotide CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Peptide and Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Peptide and Oligonucleotide CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Peptide and Oligonucleotide CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Peptide and Oligonucleotide CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Peptide and Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 46. Lonza Group Ltd. Company Details

Table 47. Lonza Group Ltd. Business Overview

Table 48. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product

Table 49. Lonza Group Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 50. Lonza Group Ltd. Recent Development

Table 51. Thermo Fisher Scientific Inc. Company Details

Table 52. Thermo Fisher Scientific Inc. Business Overview

Table 53. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product

Table 54. Thermo Fisher Scientific Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 55. Thermo Fisher Scientific Inc. Recent Development

Table 56. Merck KGaA Company Details

Table 57. Merck KGaA Business Overview

Table 58. Merck KGaA Peptide and Oligonucleotide CDMO Product

Table 59. Merck KGaA Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 60. Merck KGaA Recent Development

Table 61. Catalent, Inc. Company Details

Table 62. Catalent, Inc. Business Overview

Table 63. Catalent, Inc. Peptide and Oligonucleotide CDMO Product

Table 64. Catalent, Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 65. Catalent, Inc. Recent Development

Table 66. Genscript Biotech Corporation Company Details

Table 67. Genscript Biotech Corporation Business Overview

Table 68. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product

Table 69. Genscript Biotech Corporation Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 70. Genscript Biotech Corporation Recent Development

Table 71. Polypeptide Group Company Details

Table 72. Polypeptide Group Business Overview

Table 73. Polypeptide Group Peptide and Oligonucleotide CDMO Product

Table 74. Polypeptide Group Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 75. Polypeptide Group Recent Development

Table 76. Bachem Holding AG Company Details

Table 77. Bachem Holding AG Business Overview

Table 78. Bachem Holding AG Peptide and Oligonucleotide CDMO Product

Table 79. Bachem Holding AG Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 80. Bachem Holding AG Recent Development

Table 81. Wuxi Apptec Co., Ltd. Company Details

Table 82. Wuxi Apptec Co., Ltd. Business Overview

Table 83. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product

Table 84. Wuxi Apptec Co., Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 85. Wuxi Apptec Co., Ltd. Recent Development

Table 86. Ajinomoto Co., Inc. Company Details

Table 87. Ajinomoto Co., Inc. Business Overview

Table 88. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product

Table 89. Ajinomoto Co., Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 90. Ajinomoto Co., Inc. Recent Development

Table 91. Rentschler Biopharma SE Company Details

Table 92. Rentschler Biopharma SE Business Overview

Table 93. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product

Table 94. Rentschler Biopharma SE Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 95. Rentschler Biopharma SE Recent Development

Table 96. Corden Pharma GmbH Company Details

Table 97. Corden Pharma GmbH Business Overview

Table 98. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product

Table 99. Corden Pharma GmbH Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 100. Corden Pharma GmbH Recent Development

Table 101. Senn Chemicals AG Company Details

Table 102. Senn Chemicals AG Business Overview

Table 103. Senn Chemicals AG Peptide and Oligonucleotide CDMO Product

Table 104. Senn Chemicals AG Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 105. Senn Chemicals AG Recent Development

Table 106. Almac Group Company Details

Table 107. Almac Group Business Overview

Table 108. Almac Group Peptide and Oligonucleotide CDMO Product

Table 109. Almac Group Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 110. Almac Group Recent Development

Table 111. Lonza Custom Manufacturing Company Details

Table 112. Lonza Custom Manufacturing Business Overview

Table 113. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product

Table 114. Lonza Custom Manufacturing Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 115. Lonza Custom Manufacturing Recent Development

Table 116. Creative Peptides Company Details

Table 117. Creative Peptides Business Overview

Table 118. Creative Peptides Peptide and Oligonucleotide CDMO Product

Table 119. Creative Peptides Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 120. Creative Peptides Recent Development

Table 121. Swiss Customized Synthesis Company Details

Table 122. Swiss Customized Synthesis Business Overview

Table 123. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product

Table 124. Swiss Customized Synthesis Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 125. Swiss Customized Synthesis Recent Development

Table 126. Syngene Company Details

Table 127. Syngene Business Overview

Table 128. Syngene Peptide and Oligonucleotide CDMO Product

Table 129. Syngene Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 130. Syngene Recent Development

Table 131. Eurogentec Company Details

Table 132. Eurogentec Business Overview

Table 133. Eurogentec Peptide and Oligonucleotide CDMO Product

Table 134. Eurogentec Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 135. Eurogentec Recent Development

Table 136. Research Programs/Design for This Report

Table 137. Key Data Information from Secondary Sources

Table 138. Key Data Information from Primary Sources

Table 139. Authors List of This Report

List of Figures

Figure 1. Peptide and Oligonucleotide CDMO Picture

Figure 2. Global Peptide and Oligonucleotide CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Peptide and Oligonucleotide CDMO Market Share by Type: 2024 VS 2031

Figure 4. Peptide CDMO Features

Figure 5. Oligonucleotide CDMO Features

Figure 6. Global Peptide and Oligonucleotide CDMO Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Peptide and Oligonucleotide CDMO Market Share by Application: 2024 VS 2031

Figure 8. Pharmaceutical and Biotechnology Companies Case Studies

Figure 9. Research Institutes Case Studies

Figure 10. Others Case Studies

Figure 11. Peptide and Oligonucleotide CDMO Report Years Considered

Figure 12. Global Peptide and Oligonucleotide CDMO Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Peptide and Oligonucleotide CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Peptide and Oligonucleotide CDMO Market Share by Region: 2024 VS 2031

Figure 15. Global Peptide and Oligonucleotide CDMO Market Share by Players in 2024

Figure 16. Global Top Peptide and Oligonucleotide CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide and Oligonucleotide CDMO as of 2024)

Figure 17. The Top 10 and 5 Players Market Share by Peptide and Oligonucleotide CDMO Revenue in 2024

Figure 18. North America Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Peptide and Oligonucleotide CDMO Market Share by Country (2020-2031)

Figure 20. United States Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Peptide and Oligonucleotide CDMO Market Share by Country (2020-2031)

Figure 24. Germany Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Peptide and Oligonucleotide CDMO Market Share by Region (2020-2031)

Figure 32. China Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Peptide and Oligonucleotide CDMO Market Share by Country (2020-2031)

Figure 40. Mexico Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Peptide and Oligonucleotide CDMO Market Share by Country (2020-2031)

Figure 44. Turkey Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Lonza Group Ltd. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 48. Thermo Fisher Scientific Inc. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 49. Merck KGaA Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 50. Catalent, Inc. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 51. Genscript Biotech Corporation Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 52. Polypeptide Group Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 53. Bachem Holding AG Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 54. Wuxi Apptec Co., Ltd. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 55. Ajinomoto Co., Inc. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 56. Rentschler Biopharma SE Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 57. Corden Pharma GmbH Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 58. Senn Chemicals AG Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 59. Almac Group Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 60. Lonza Custom Manufacturing Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 61. Creative Peptides Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 62. Swiss Customized Synthesis Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 63. Syngene Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 64. Eurogentec Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions